TobaccoReporter logo

Tag: risk

  • Study: Health Risks of Chewing Tobacco Need More Attention

    Study: Health Risks of Chewing Tobacco Need More Attention

    A new global study published by Nature Communications said that chewing tobacco should be receiving more attention for the significant health risks it causes, linking it to multiple forms of cancer and stroke (evidence for heart disease remains limited). Researchers found sufficient evidence connecting chewing tobacco use to six major health outcomes—including esophageal, lip and oral cavity, laryngeal, nasopharyngeal, and other pharynx cancers, as well as stroke. These findings reinforce previous evidence that chewing tobacco is a carcinogen and highlight its growing health impact, particularly in South Asia, where over 80% of the world’s 273 million users reside.

    The study said its systematic review and meta-analysis, which analyzed over five decades of research, is the most comprehensive evaluation to date focused specifically on chewing tobacco, distinct from other smokeless tobacco products. The study’s authors called for urgent policy action to integrate chewing tobacco into global and national tobacco control programs, improve cessation support, and expand high-quality research.

  • FDA Posts New Materials for IQOS Renewal Applications

    FDA Posts New Materials for IQOS Renewal Applications

    The U.S. Food and Drug Administration announced today that its Tobacco Products Scientific Advisory Committee (TPSAC) will convene October 7, to evaluate the renewal applications of Philip Morris Products S.A. for its IQOS 2.4 and IQOS 3.0 heated-tobacco systems and associated HeatSticks. These devices were originally granted Modified Risk Tobacco Product (MRTP) orders in 2020 and 2022, allowing the marketing of reduced-exposure claims—specifically, that heating (not burning) tobacco significantly lowers exposure to harmful chemicals.

    The renewal will hinge on whether PMI can demonstrate that post-market evidence continues to support those claims under section 911(g)(2) of the Food, Drug, and Cosmetic Act.  The FDA has republished redacted application materials and opened a public comment period; speakers at the TPSAC meeting may submit data supporting or critiquing PMI’s dossier.

    “A vital mission of FDA is to make tobacco-related disease and death a part of America’s past,” officials from PMI said in a statement. “Smoke-free products, like IQOS, play a critical role in helping achieve that mission and provide adults who smoke with a real opportunity to change. IQOS, when marketed with the reduced-exposure claim, promotes complete switching and reduction in cigarette consumption.”

    Should the renewal be approved, PMI would retain authority to market IQOS with MRTP claims; if rejected, those claims could expire, undermining the company’s “reduced-exposure” positioning in the U.S. market.

    The outcome will not only be of interest for PMI, but for the broader heated tobacco and smoke-free sectors looking for regulatory precedents.

  • South Africa Debating Vape’s Role in Harm Reduction

    South Africa Debating Vape’s Role in Harm Reduction

    South Africa’s Parliament is reviewing the Tobacco Products and Electronic Delivery Systems Control Bill, which proposes strict regulations on all nicotine products—treating e-cigarettes, heated tobacco, and traditional cigarettes the same. Proponents of harm-reducing products warn that treating all nicotine products equally could stifle innovation and keep safer alternatives out of reach.

    The debate comes at a critical juncture for South Africa’s public health and economy. The current bill includes plain packaging, graphic health warnings, a ban on advertising, public vaping restrictions, and limits on vape flavors. Industry leaders like Philip Morris International (PMI) argue this approach ignores scientific evidence showing reduced harm from smoke-free products, urging a differentiated regulatory framework like those in the UK and Japan.

    PMI says equal restrictions discourage smokers from switching to less harmful alternatives. But health groups and some lawmakers remain cautious, citing youth vaping risks and insufficient long-term safety data.